Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 07, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of...
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
October 03, 2024 08:00 ET
|
Pacira BioSciences
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) --...
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
September 26, 2024 08:00 ET
|
Pacira BioSciences
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2024 16:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
August 09, 2024 15:21 ET
|
Pacira BioSciences
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Reports Second Quarter 2024 Financial Results
July 30, 2024 16:00 ET
|
Pacira BioSciences
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
July 23, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on...
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
July 10, 2024 16:19 ET
|
Pacira BioSciences
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient...
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare...
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
May 10, 2024 07:00 ET
|
Pacira BioSciences
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029...